Page 87 - CIBERESP2016-ENG

Most relevant scientific articles
• Kissling E., Nunes B., Robertson C., Valenciano M., Reuss A., Larrauri A. et al. I-MOVE multicentre case–control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Eurosurveillance. 2016;21(16).
• Gherasim A., Pozo F., de Mateo S., Aspiritxaga Gamarra I., García-Cenoz M., Vega T. et al. Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014-15. Vaccine. 2016.
• Álvaro-Meca A., Díaz A., De Miguel Díez J., Resino R., Resino S. Environmental factors related to pulmonary tuberculosis in HIV-infected patients in the combined antiretroviral therapy (cART) era. PLoS ONE. 2016;11(11).
• Solano R., Masa-Calles J., Garib Z., Grullón P., Santiago S.L., Brache A. et al. Epidemiology of pertussis in two Ibero-American countries with different vaccination policies: Lessons derived from different surveillance systems. BMC Public Health. 2016;16(1).
• Cayla J.A., Domínguez A., Rodríguez Valín E., de Ory F., Vázquez A., Fortuny C. Zika virus infection: a new public health emergency with great media impact. Gaceta Sanitaria. 2016;30(6):468-471.
Highlights
The research activity of the G32 group is reflected in the participation in five national and seven international research projects, with the collaboration of other CIBERESP groups.
Research on the impact and effectiveness on the Epidemiology of vaccine preventables diseases is reflected in two international research projects: one form Horizon 20202 “I-Move+ Integrated Monitoring of Vaccine Effectiveness in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly” (EU 634446) and the ECDC call
for tender” Assessing the impact of vaccination with conjugate vaccines on the epidemiology of invasive pneumococcal disease in the EU/EEA (OJ/15/06/2015-PROC/2015/020). Así mismo, en el Subprograma de investigación sobre Gripe del PREVICET.
Our research in influenza vaccine effectiveness contributed to GIVE Report 2015 (The Global Influenza Vaccine Effectiveness Collaboration), with the aim of supporting WHO in the two annual selection processes of the influenza virus strains to include in the seasonal vaccine for the next flu season.
Related to emerging infectious diseases we are participating in the project “Research on Enterovirus infections causing serious neurological and systemic pathologies in children.” Likewise, we continue searching evidence to advance in the elimination of measles and rubella, participating in the project “Epidemiological and Virological Analysis of viral agents included in MMR: New Challenges.
The development of spatio-temporal models for the study of the risk of acquiring and developing infectious diseases has become in the AES2016 project “Integration of climate information for the improvement
of surveillance of communicable diseases”, which has served as a basis for the development of a new subprogramme under the PREVICET program “Vector-borne infections, environmental factors and climate change”.
The protocol of the Surveillance of Health Care Associated Infections has been approved by the National Public Health Commission. In the next future it implementation will star in Spain with a pilot study of Surveillance of Health Care Associated Infections in surgical sites.ç
The G32 group participates in the Strategic National Action Plan for reducing the risk of antibiotic resistance spreading. This Plan was supported from the National Spanish Agency for Drugs and Sanitary Products. We also collaborated in the elaboration of the Annual Report of the Strategic Plan.
ESP
Research groups 87